10x Genomics, Inc.: stock overview

TXGNASDAQHealthcare · Laboratory Analytical Instruments

Price

$58.19

November 13, 2026Market cap $7.4B

DCF calculator

What Ploutos Investor adds for 10x Genomics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 9 fiscal years, from 2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

10x Genomics had revenue of $619M over the last 12 months and a net loss of $67M. Revenue grew by 16.6% a year on average over the last 5 years. It holds more cash than debt, by $576M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$7.4B
128M shares
P/E
–
Revenue, 12 months
$619M
+16.6% a year over 5 years
Net margin
-10.8%
2025: -6.8%, above 39% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+1.9% a year over 2 years

  • 202510-K
    Revenue$643M
  • 202410-K
    Revenue$611M
  • 202310-K
    Revenue$619M

Fiscal years in figures

TXG's revenue, profit, cash flow and dividend with each year-end price, from 2017 to 2022, 6 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $2.1B
$7.4B
Enterprise value 
$6.9B
P/E 
–
EV / EBIT 
–
EV / Revenue 
11.1
P/B 3-year median: 2.6
8.9
FCF yield 3-year median: -0.3%
1.3%
Earnings yield 3-year median: -3.9%
–

Profitability

Gross margin 
71.9%
Operating margin 
-11.7%
Net margin 3-year median: -29.9%
-10.8%
ROIC 
-7.0%
ROIC, 5-year average 
-15.5%
ROE 
-8.3%

Growth

Revenue, yearly change 
+5.3%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+16.6%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$576M
Total debt 
$76M
Of which operating leases 
$76M
Net cash 
$576M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
5.12

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+4.4%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).

Gross margin

69.1%

Above 77% of the 161 companies in its industry, and 86% of all.

Operating margin

-9.5%

Above 34% of the 186 companies in its industry, and 20% of all.

Net margin

-6.8%

Above 39% of the 189 companies in its industry, and 22% of all.

ROE

-5.5%

Above 38% of the 174 companies in its industry, and 23% of all.

ROA

-4.2%

Above 41% of the 190 companies in its industry, and 22% of all.

Revenue growth

5.3%

Above 41% of the 186 companies in its industry, and 47% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
10x Genomics, Inc.
CIK
1770787
Exchange
NASDAQ
Industry (SIC)
3826 · Laboratory Analytical Instruments
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
128M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do 10x Genomics's filings show?

These are 10x Genomics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about TXG

Didn't find what you were looking for?

Ask us
What is TXG's market cap?

10x Genomics, Inc.'s market cap is $7.4B, at a price of $58.19 on November 13, 2026 and 128M shares.

How much revenue does TXG have?

10x Genomics had revenue of $619M over the last 12 months. Over the last 5 years it changed by +16.6% a year on average.

Does TXG pay a dividend?

No. 10x Genomics paid no regular dividend over the last 12 months.

Where do the figures come from?

From 10x Genomics, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.